Assessing the intrinsic properties of drug candidates with the latest DMPK studies.
PROVIDING YOUR PIPELINES WITH THE SAFETY AND CERTAINTY THEY NEED.
When developing a drug, and before releasing it to the market, there are certain milestones that cannot be bypassed when assessing a drug’s ADME properties and safety. This translates to a need for impeccable DMPK studies.
With a system that is in compliant with U.S. Food and Drug Administration (FDA), European Medical Agency (EMA), and National Medical Products Administration (NMPA) regulations, animal facilities fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC), and highly experienced DMPK scientific team, PharmaLegacy has helped clients worldwide to speed up their drug discovery processes.
DMPK studies demand flexibility. Can yours meet their goals?
When it comes to DMPK, flexibility is paramount. The right assay and instrumentation are all critical to ensuring you can meet your study goals and obtain meaningful, clinically relevant data.
Download our DMPK brochure and see how PharmaLegacy is equipped to ensure you get the answers you need, no matter how challenging the study.
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies